Stock Analysis

Biofactory Full Year 2023 Earnings: zł0.10 loss per share (vs zł0.56 profit in FY 2022)

WSE:BFC
Source: Shutterstock

Biofactory (WSE:BFC) Full Year 2023 Results

Key Financial Results

  • Revenue: zł14.6m (down 13% from FY 2022).
  • Net loss: zł196.0k (down by 119% from zł1.06m profit in FY 2022).
  • zł0.10 loss per share (down from zł0.56 profit in FY 2022).
earnings-and-revenue-history
WSE:BFC Earnings and Revenue History February 19th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biofactory shares are up 16% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Biofactory has 5 warning signs (and 4 which don't sit too well with us) we think you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether Biofactory is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.